针对阿尔茨海默病的粉样β向抗体的数据驱动建模
Kobra Rabiei1, Jeffrey R Petrella2, Suzanne Lenhart3
1Department of Mathematics, Penn State University, University Park, PA, USA.
NPJ systems biology and applications
|November 21, 2025
概括
这项研究模拟了阿尔茨海默病 (AD) 的粉样蛋白β聚合,以找到最佳的药物剂量. 多纳内马布显示有毒粉样纤维的最大减少,平衡有效性和安全性.
科学领域:
- 神经科学是一个神经科学.
- 生物数学是生物数学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 涉及粉样β (Aβ) 积累,与认知能力下降有关.
- 目前的治疗方法,如单克隆抗体,在优化疗效和最大限度地减少ARIA等副作用方面面临挑战.
研究的目的:
- 开发一个数学框架,模拟Aβ聚合动态.
- 建立一个最佳的控制框架来确定药物剂量,以减少有毒的Aβ物种和尽量减少不良影响.
主要方法:
- 利用质量作用动力学和粗粒度建模用于Aβ聚合.
- 采用参数估计,灵敏度分析和数据驱动的校准用于模型验证.
- 应用一个最佳的控制框架来确定理想的药物剂量策略.
主要成果:
- 该模型准确地捕获了从单体到纤维的Aβ聚合.
- 与其他模拟干预措施相比,donanemab显示了粉样纤维的最实质性的减少.
- 该框架为平衡治疗益处和潜在副作用 (如ARIA) 提供了洞察力.
结论:
- 开发的数学框架为优化阿尔茨海默病治疗策略提供了定量方法.
- 这些发现支持了像Donanemab这样的向疗法在减少有毒Aβ聚合物的潜力.
- 这项研究为阿尔茨海默氏症的个性化医学提供了基础,通过平衡治疗疗效和患者安全.
相关概念视频
01:22Alzheimer's Disease: Treatment
772
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
772
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K